Alexander Zverev confirmed he lives with type-1 diabetes after administering an insulin injection during the 2026 French Open final [1].
The revelation highlights the physical challenges elite athletes face when managing chronic health conditions while competing at the highest level of professional sports.
Zverev was competing at Court Philippe-Chatrier at Roland-Garros in Paris, France, when he took the medication [1]. The injection was necessary to manage his blood-sugar levels during the intensity of the championship match [2].
Reports indicate that Zverev has lived with the condition since he was four years old [2]. Managing type-1 diabetes requires constant monitoring and insulin administration to prevent dangerous fluctuations in glucose levels, which can be exacerbated by the extreme physical exertion of a Grand Slam final.
While Zverev has maintained a top-tier professional career, the public nature of the medical requirement during the 2026 final brings visibility to the condition [1]. The administration of the shot occurred in the midst of the high-stakes environment of the French Open, illustrating the rigorous maintenance required for his health and athletic performance [1].
Zverev's mother said the athlete faced difficulties in the beginning of his journey with the disease and showed determination to pursue a tennis dream despite the diagnosis [2].
“Zverev administered an insulin injection during the French Open final”
The public disclosure of Zverev's condition underscores the viability of professional athletic careers for individuals with type-1 diabetes. By managing a chronic illness at the pinnacle of a demanding sport like tennis, Zverev provides a visible precedent for how medical technology and disciplined health management can coexist with elite performance.
